市場調査レポート

商品コード

1140055

抗核抗体検査市場：製品別、技術別、用途別、最終用途別：世界の機会分析および産業予測、2021-2031年

Antinuclear Antibody Test Market By Product, By Technique, By Application, By End-use : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年08月01日 | 発行: Allied Market Research

| ページ情報: 英文 329 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,820 912,343円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,540 1,025,210円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,870 1,547,221円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

抗核抗体検査の世界市場は、2022年から2031年まで14.97%のCAGRで、2021年の12億9490万米ドルから成長し、2030年にかけて49億9940万米ドルに達すると予測されています。

抗核抗体（ANA）検査は、自己免疫疾患の症状を示す患者に自己抗体が存在するかどうかを調べるために実施される血液検査です。自己抗体は通常、体内の細胞に対して作られるもので、血清中に存在します。

抗核抗体検査の市場拡大は、政府の医療保険、自己免疫疾患の啓発キャンペーンの増加、および償還規制によって推進されています。例えば、世界ループス連盟（WLF）は、ループス患者を支援することを目的に、6大陸75カ国から約250のループス組織が加盟している同盟組織です。WLFは、一般の人々へのループス認知を促進し、ループス患者がより良い医療施設を利用できるように、患者の抗核抗体検査の実施を支援するなどの活動を行っています。

ANA検査を担当する人は、技術と疾患の両方について知識が必要です。両方を理解していなければ、検査を完了させることはできません。予想される世界市場の最大の障壁は、検査キットを操作する熟練スタッフの不足であると考えられます。また、検査費用が高額であるため、誰もが検査を受けることができず、予測期間を通じて市場の成長を阻害することが予想されます。

抗核抗体検査は、COVID-19のパンデミックから恩恵を受け、パンデミックの段階で大きな成長を遂げると予測されています。抗核抗体検査はますます一般的になってきており、それがこの市場成長の主な原因となっています。これらの検査は、人の体内に自己免疫疾患が存在することを示すものであり、その検出は極めて重要です。さらに、COVID陽性患者における自己免疫疾患の有病率の上昇により、市場は開拓されています。これらの要因はすべて、COVID-19が流行している間の市場拡大を支えています。

市場の定義と範囲
主な調査結果
- 主な投資ポケット
ポーターのファイブフォース分析
主要企業のポジショニング
市場力学
- 促進要因
- 抑制要因
- 機会
COVID-19 影響分析
規制ガイドライン
バリューチェーン分析
市場シェア分析
主要規制の分析
特許情勢

第4章抗核抗体検査市場：製品別

概要
- 市場規模・予測
試薬・アッセイキット
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
システム
- 主要な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ソフトウェア＆サービス
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章抗核抗体検査市場：技術別

概要
- 市場規模・予測
ELISA
- 主な市場動向・成長要因・機会
- 市場規模・予測：地域別
- 市場分析：国別
免疫蛍光測定法（Immunofluorescence Assay
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
マルチプレックスアッセイ
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章抗核抗体検査市場：応用分野別

概要
- 市場規模・予測
関節リウマチ
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
全身性エリテマトーデス
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
シェーグレン症候群
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
強皮症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章抗核抗体検査市場：エンドユース別

概要
- 市場規模・予測
病院
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別
クリニカルラボラトリー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
医師オフィス向けラボラトリー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第8章抗糖尿素検査市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米市場規模・予測：製品別
- 北米市場規模・予測：技術別
- 北米市場規模・予測：用途別
- 北米市場規模・予測：エンドユーザー別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州の市場規模・予測：製品別
- 欧州市場規模・予測：技術別
- 欧州市場規模・予測：用途別
- 欧州市場規模・予測：エンドユーザー別
- 欧州市場規模・予測：国別
  - ドイツ
  - 英国
  - フランス
  - スペイン
  - イタリア
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：製品別
- アジア太平洋地域の市場規模・予測：技術別
- アジア太平洋地域の市場規模・予測：用途別
- アジア太平洋地域の市場規模・予測：エンドユース別
- アジア太平洋地域の市場規模・予測：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - オーストラリア
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：製品別
- LAMEAの市場規模・予測：技法別
- LAMEAの市場規模・予測：用途別
- LAMEAの市場規模・予測：エンドユーザー別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - UAE
  - 南アフリカ共和国
  - LAMEAの残りの地域

第9章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第10章企業プロファイル

erba diagnostics mannheim gmbh
Bio-Rad Laboratories, Inc.
Trinity Biotech Plc.
Thermo Fisher Scientific, Inc.
Antibodies Incorporated
euroimmun medizinische labordiagnostika ag
Immuno Concepts NA Ltd.
Inova Diagnostics, Inc.
ZEUS Scientific, Inc.

図表

LIST OF TABLES

TABLE 1. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 2. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR REAGENTS & ASSAY KITS, BY REGION , 2021-2031,($MILLION)
TABLE 3. ANTINUCLEAR ANTIBODY TEST MARKET FOR REAGENTS & ASSAY KITS BY COUNTRY, 2021-2031,($MILLION)
TABLE 4. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SYSTEMS, BY REGION , 2021-2031,($MILLION)
TABLE 5. ANTINUCLEAR ANTIBODY TEST MARKET FOR SYSTEMS BY COUNTRY, 2021-2031,($MILLION)
TABLE 6. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SOFTWARE & SERVICES, BY REGION , 2021-2031,($MILLION)
TABLE 7. ANTINUCLEAR ANTIBODY TEST MARKET FOR SOFTWARE & SERVICES BY COUNTRY, 2021-2031,($MILLION)
TABLE 8. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 9. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR ELISA, BY REGION , 2021-2031,($MILLION)
TABLE 10. ANTINUCLEAR ANTIBODY TEST MARKET FOR ELISA BY COUNTRY, 2021-2031,($MILLION)
TABLE 11. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR IMMUNOFLUORESCENCE ASSAY, BY REGION , 2021-2031,($MILLION)
TABLE 12. ANTINUCLEAR ANTIBODY TEST MARKET FOR IMMUNOFLUORESCENCE ASSAY BY COUNTRY, 2021-2031,($MILLION)
TABLE 13. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR MULTIPLEX ASSAY, BY REGION , 2021-2031,($MILLION)
TABLE 14. ANTINUCLEAR ANTIBODY TEST MARKET FOR MULTIPLEX ASSAY BY COUNTRY, 2021-2031,($MILLION)
TABLE 15. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 16. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR RHEUMATOID ARTHRITIS, BY REGION , 2021-2031,($MILLION)
TABLE 17. ANTINUCLEAR ANTIBODY TEST MARKET FOR RHEUMATOID ARTHRITIS BY COUNTRY, 2021-2031,($MILLION)
TABLE 18. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION , 2021-2031,($MILLION)
TABLE 19. ANTINUCLEAR ANTIBODY TEST MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY COUNTRY, 2021-2031,($MILLION)
TABLE 20. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SJOGREN'S SYNDROME, BY REGION , 2021-2031,($MILLION)
TABLE 21. ANTINUCLEAR ANTIBODY TEST MARKET FOR SJOGREN'S SYNDROME BY COUNTRY, 2021-2031,($MILLION)
TABLE 22. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SCLERODERMA, BY REGION , 2021-2031,($MILLION)
TABLE 23. ANTINUCLEAR ANTIBODY TEST MARKET FOR SCLERODERMA BY COUNTRY, 2021-2031,($MILLION)
TABLE 24. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
TABLE 25. ANTINUCLEAR ANTIBODY TEST MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
TABLE 26. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 27. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR HOSPITALS, BY REGION , 2021-2031,($MILLION)
TABLE 28. ANTINUCLEAR ANTIBODY TEST MARKET FOR HOSPITALS BY COUNTRY, 2021-2031,($MILLION)
TABLE 29. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR CLINICAL LABORATORIES, BY REGION , 2021-2031,($MILLION)
TABLE 30. ANTINUCLEAR ANTIBODY TEST MARKET FOR CLINICAL LABORATORIES BY COUNTRY, 2021-2031,($MILLION)
TABLE 31. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR PHYSICIAN OFFICE LABORATORIES, BY REGION , 2021-2031,($MILLION)
TABLE 32. ANTINUCLEAR ANTIBODY TEST MARKET FOR PHYSICIAN OFFICE LABORATORIES BY COUNTRY, 2021-2031,($MILLION)
TABLE 33. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
TABLE 34. ANTINUCLEAR ANTIBODY TEST MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
TABLE 35. ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION, 2021-2031,($MILLION)
TABLE 36. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 37. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 38. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 39. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 40. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 41. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 42. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 43. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 44. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 45. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 46. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 47. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 48. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 49. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 50. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 51. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 52. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 53. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 54. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 55. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 56. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 57. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 58. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 59. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 60. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 61. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 62. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 63. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 64. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 65. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 66. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 67. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 68. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 69. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 70. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 71. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 72. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 73. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 74. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 75. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 76. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 77. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 78. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 79. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 80. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 81. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 82. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 83. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 84. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 85. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 86. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 87. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 88. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 89. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 90. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 91. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 92. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 93. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 94. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 95. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 96. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 97. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 98. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 99. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 100. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 101. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 102. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 103. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 104. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 105. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 106. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 107. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 108. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 109. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 110. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 111. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 112. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 113. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 114. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 115. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 116. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 117. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 118. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 119. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 120. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 121. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 122. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 123. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 124. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 125. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 126. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 127. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 128. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 129. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 130. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 131. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 132. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
TABLE 133. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
TABLE 134. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
TABLE 135. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
TABLE 136.ERBA DIAGNOSTICS MANNHEIM GMBH: COMPANY SNAPSHOT
TABLE 137.ERBA DIAGNOSTICS MANNHEIM GMBH: OPERATING SEGMENTS
TABLE 138.ERBA DIAGNOSTICS MANNHEIM GMBH: PRODUCT PORTFOLIO
TABLE 139.ERBA DIAGNOSTICS MANNHEIM GMBH: NET SALES,
TABLE 140.ERBA DIAGNOSTICS MANNHEIM GMBH: KEY STRATERGIES
TABLE 141.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 142.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 143.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 144.BIO-RAD LABORATORIES, INC.: NET SALES,
TABLE 145.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 146.TRINITY BIOTECH PLC.: COMPANY SNAPSHOT
TABLE 147.TRINITY BIOTECH PLC.: OPERATING SEGMENTS
TABLE 148.TRINITY BIOTECH PLC.: PRODUCT PORTFOLIO
TABLE 149.TRINITY BIOTECH PLC.: NET SALES,
TABLE 150.TRINITY BIOTECH PLC.: KEY STRATERGIES
TABLE 151.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 152.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 153.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 154.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 155.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
TABLE 156.ANTIBODIES INCORPORATED: COMPANY SNAPSHOT
TABLE 157.ANTIBODIES INCORPORATED: OPERATING SEGMENTS
TABLE 158.ANTIBODIES INCORPORATED: PRODUCT PORTFOLIO
TABLE 159.ANTIBODIES INCORPORATED: NET SALES,
TABLE 160.ANTIBODIES INCORPORATED: KEY STRATERGIES
TABLE 161.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY SNAPSHOT
TABLE 162.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: OPERATING SEGMENTS
TABLE 163.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: PRODUCT PORTFOLIO
TABLE 164.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: NET SALES,
TABLE 165.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: KEY STRATERGIES
TABLE 166.IMMUNO CONCEPTS NA LTD.: COMPANY SNAPSHOT
TABLE 167.IMMUNO CONCEPTS NA LTD.: OPERATING SEGMENTS
TABLE 168.IMMUNO CONCEPTS NA LTD.: PRODUCT PORTFOLIO
TABLE 169.IMMUNO CONCEPTS NA LTD.: NET SALES,
TABLE 170.IMMUNO CONCEPTS NA LTD.: KEY STRATERGIES
TABLE 171.INOVA DIAGNOSTICS, INC.: COMPANY SNAPSHOT
TABLE 172.INOVA DIAGNOSTICS, INC.: OPERATING SEGMENTS
TABLE 173.INOVA DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
TABLE 174.INOVA DIAGNOSTICS, INC.: NET SALES,
TABLE 175.INOVA DIAGNOSTICS, INC.: KEY STRATERGIES
TABLE 176.ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 177.ZEUS SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 178.ZEUS SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 179.ZEUS SCIENTIFIC, INC.: NET SALES,
TABLE 180.ZEUS SCIENTIFIC, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.ANTINUCLEAR ANTIBODY TEST MARKET SEGMENTATION
FIGURE 2.ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031
FIGURE 3.ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ANTINUCLEAR ANTIBODY TEST MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.REGULATORY GUIDELINES
FIGURE 13.VALUE CHAIN ANALYSIS
FIGURE 14.MARKET SHARE ANALYSIS
FIGURE 15.KEY REGULATION ANALYSIS
FIGURE 16.PATENT ANALYSIS BY COMPANY
FIGURE 17.PATENT ANALYSIS BY COUNTRY
FIGURE 18.ANTINUCLEAR ANTIBODY TEST MARKET,BY PRODUCT,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF REAGENTS & ASSAY KITS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SYSTEMS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SOFTWARE & SERVICES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 22.ANTINUCLEAR ANTIBODY TEST MARKET,BY TECHNIQUE,2021(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ELISA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF IMMUNOFLUORESCENCE ASSAY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MULTIPLEX ASSAY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 26.ANTINUCLEAR ANTIBODY TEST MARKET,BY APPLICATION,2021(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF RHEUMATOID ARTHRITIS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SJOGREN'S SYNDROME ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF SCLERODERMA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 32.ANTINUCLEAR ANTIBODY TEST MARKET,BY END-USE,2021(%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF HOSPITALS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF CLINICAL LABORATORIES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 35.COMPARATIVE SHARE ANALYSIS OF PHYSICIAN OFFICE LABORATORIES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 36.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
FIGURE 37.ANTINUCLEAR ANTIBODY TEST MARKET BY REGION,2021
FIGURE 38.U.S. ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 39.CANADA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 40.MEXICO ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 41.GERMANY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 42.UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 43.FRANCE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 44.SPAIN ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 45.ITALY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 46.REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 47.CHINA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 48.JAPAN ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 49.INDIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 50.SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 51.AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 52.REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 53.BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 54.SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 55.UAE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 56.SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 57.REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
FIGURE 58. TOP WINNING STRATEGIES, BY YEAR
FIGURE 59. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 60. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 61.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 62.COMPETITIVE DASHBOARD
FIGURE 63.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 64.ERBA DIAGNOSTICS MANNHEIM GMBH.: NET SALES ,($MILLION)
FIGURE 65.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
FIGURE 66.TRINITY BIOTECH PLC..: NET SALES ,($MILLION)
FIGURE 67.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
FIGURE 68.ANTIBODIES INCORPORATED.: NET SALES ,($MILLION)
FIGURE 69.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG.: NET SALES ,($MILLION)
FIGURE 70.IMMUNO CONCEPTS NA LTD..: NET SALES ,($MILLION)
FIGURE 71.INOVA DIAGNOSTICS, INC..: NET SALES ,($MILLION)
FIGURE 72.ZEUS SCIENTIFIC, INC..: NET SALES ,($MILLION)

Product Code: A03912

The global antinuclear antibody test market is envisioned to garner $ 4,999.4million by 2030, growing from $ 1,294.9 million in 2021 at a CAGR of 14.97% from 2022 to 2031.

An anti-nuclear antibody (ANA) test is a blood test performed to find out whether there are any autoantibodies present in the patient showing symptoms of autoimmune diseases. Autoantibodies are usually made by the body against its own cells, present in the serum.

The market expansion of anti-nuclear antibody testing is driven by government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, the World Lupus Federation (WLF) is an alliance of about 250 lupus organizations from 75 nations across six continents with the goal of helping lupus patients. WLF promotes lupus awareness among the general public and gives lupus patients access to improved medical care facilities like providing assistance in conducting antinuclear antibody tests of the patients.

The individual in charge of doing ANA tests needs to be knowledgeable about both technology and the condition. A person cannot complete the test without comprehending both. The greatest barrier for the global market in the anticipated term is expected to be a lack of skilled staff to operate the testing kits. Additionally, everyone cannot afford the test because of its high cost, which is expected to impede the market's growth throughout the projected time.

Antinuclear antibody testing is anticipated to benefit from the COVID-19 pandemic and experience substantial growth during the pandemic stage. Antinuclear antibody testing has become increasingly popular, which is the main cause of this market growth. These tests demonstrate the existence of autoimmune illnesses in a person's body, making their detection vital. Additionally, the market is developing due to the rising prevalence of autoimmune illnesses in the COVID positive patients. All of these factors support market expansion during the COVID-19 epidemic.

The key players profiled in this report include: Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antinuclear antibody test market analysis from 2021 to 2031 to identify the prevailing antinuclear antibody test market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antinuclear antibody test market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antinuclear antibody test market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

Reagents Assay Kits
Systems
Software Services

By Technique

ELISA
Immunofluorescence Assay
Multiplex Assay

By Application

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Sjogren's Syndrome
Scleroderma
Others

By End-use

Hospitals
Clinical Laboratories
Physician Office Laboratories
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- erba diagnostics mannheim gmbh
- Bio-Rad Laboratories, Inc.
- Trinity Biotech Plc.
- Thermo Fisher Scientific, Inc.
- Antibodies Incorporated
- euroimmun medizinische labordiagnostika ag
- Immuno Concepts NA Ltd.
- Inova Diagnostics, Inc.
- ZEUS Scientific, Inc.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Regulatory Guidelines
3.8.Value Chain Analysis
3.9.Market Share Analysis
3.10.Key Regulation Analysis
3.11.Patent Landscape

CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Reagents & Assay Kits
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Systems
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Software & Services
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 ELISA
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Immunofluorescence Assay
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Multiplex Assay
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Rheumatoid Arthritis
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Systemic Lupus Erythematosus
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Sjogren's Syndrome
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
6.5 Scleroderma
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
6.6 Others
- 6.6.1 Key market trends, growth factors and opportunities
- 6.6.2 Market size and forecast, by region
- 6.6.3 Market analysis by country

CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE

7.1 Overview
- 7.1.1 Market size and forecast
7.2 Hospitals
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
7.3 Clinical Laboratories
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
7.4 Physician Office Laboratories
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
7.5 Others
- 7.5.1 Key market trends, growth factors and opportunities
- 7.5.2 Market size and forecast, by region
- 7.5.3 Market analysis by country

CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION

8.1 Overview
- 8.1.1 Market size and forecast
8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Product
- 8.2.3 North America Market size and forecast, by Technique
- 8.2.4 North America Market size and forecast, by Application
- 8.2.5 North America Market size and forecast, by End-use
- 8.2.6 North America Market size and forecast, by country
  - 8.2.6.1 U.S.
  - 8.2.6.1.1 Market size and forecast, by Product
  - 8.2.6.1.2 Market size and forecast, by Technique
  - 8.2.6.1.3 Market size and forecast, by Application
  - 8.2.6.1.4 Market size and forecast, by End-use
  - 8.2.6.2 Canada
  - 8.2.6.2.1 Market size and forecast, by Product
  - 8.2.6.2.2 Market size and forecast, by Technique
  - 8.2.6.2.3 Market size and forecast, by Application
  - 8.2.6.2.4 Market size and forecast, by End-use
  - 8.2.6.3 Mexico
  - 8.2.6.3.1 Market size and forecast, by Product
  - 8.2.6.3.2 Market size and forecast, by Technique
  - 8.2.6.3.3 Market size and forecast, by Application
  - 8.2.6.3.4 Market size and forecast, by End-use
8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Product
- 8.3.3 Europe Market size and forecast, by Technique
- 8.3.4 Europe Market size and forecast, by Application
- 8.3.5 Europe Market size and forecast, by End-use
- 8.3.6 Europe Market size and forecast, by country
  - 8.3.6.1 Germany
  - 8.3.6.1.1 Market size and forecast, by Product
  - 8.3.6.1.2 Market size and forecast, by Technique
  - 8.3.6.1.3 Market size and forecast, by Application
  - 8.3.6.1.4 Market size and forecast, by End-use
  - 8.3.6.2 United Kingdom
  - 8.3.6.2.1 Market size and forecast, by Product
  - 8.3.6.2.2 Market size and forecast, by Technique
  - 8.3.6.2.3 Market size and forecast, by Application
  - 8.3.6.2.4 Market size and forecast, by End-use
  - 8.3.6.3 France
  - 8.3.6.3.1 Market size and forecast, by Product
  - 8.3.6.3.2 Market size and forecast, by Technique
  - 8.3.6.3.3 Market size and forecast, by Application
  - 8.3.6.3.4 Market size and forecast, by End-use
  - 8.3.6.4 Spain
  - 8.3.6.4.1 Market size and forecast, by Product
  - 8.3.6.4.2 Market size and forecast, by Technique
  - 8.3.6.4.3 Market size and forecast, by Application
  - 8.3.6.4.4 Market size and forecast, by End-use
  - 8.3.6.5 Italy
  - 8.3.6.5.1 Market size and forecast, by Product
  - 8.3.6.5.2 Market size and forecast, by Technique
  - 8.3.6.5.3 Market size and forecast, by Application
  - 8.3.6.5.4 Market size and forecast, by End-use
  - 8.3.6.6 Rest of Europe
  - 8.3.6.6.1 Market size and forecast, by Product
  - 8.3.6.6.2 Market size and forecast, by Technique
  - 8.3.6.6.3 Market size and forecast, by Application
  - 8.3.6.6.4 Market size and forecast, by End-use
8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Product
- 8.4.3 Asia-Pacific Market size and forecast, by Technique
- 8.4.4 Asia-Pacific Market size and forecast, by Application
- 8.4.5 Asia-Pacific Market size and forecast, by End-use
- 8.4.6 Asia-Pacific Market size and forecast, by country
  - 8.4.6.1 China
  - 8.4.6.1.1 Market size and forecast, by Product
  - 8.4.6.1.2 Market size and forecast, by Technique
  - 8.4.6.1.3 Market size and forecast, by Application
  - 8.4.6.1.4 Market size and forecast, by End-use
  - 8.4.6.2 Japan
  - 8.4.6.2.1 Market size and forecast, by Product
  - 8.4.6.2.2 Market size and forecast, by Technique
  - 8.4.6.2.3 Market size and forecast, by Application
  - 8.4.6.2.4 Market size and forecast, by End-use
  - 8.4.6.3 India
  - 8.4.6.3.1 Market size and forecast, by Product
  - 8.4.6.3.2 Market size and forecast, by Technique
  - 8.4.6.3.3 Market size and forecast, by Application
  - 8.4.6.3.4 Market size and forecast, by End-use
  - 8.4.6.4 South Korea
  - 8.4.6.4.1 Market size and forecast, by Product
  - 8.4.6.4.2 Market size and forecast, by Technique
  - 8.4.6.4.3 Market size and forecast, by Application
  - 8.4.6.4.4 Market size and forecast, by End-use
  - 8.4.6.5 Australia
  - 8.4.6.5.1 Market size and forecast, by Product
  - 8.4.6.5.2 Market size and forecast, by Technique
  - 8.4.6.5.3 Market size and forecast, by Application
  - 8.4.6.5.4 Market size and forecast, by End-use
  - 8.4.6.6 Rest Of Asia Pacific
  - 8.4.6.6.1 Market size and forecast, by Product
  - 8.4.6.6.2 Market size and forecast, by Technique
  - 8.4.6.6.3 Market size and forecast, by Application
  - 8.4.6.6.4 Market size and forecast, by End-use
8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Product
- 8.5.3 LAMEA Market size and forecast, by Technique
- 8.5.4 LAMEA Market size and forecast, by Application
- 8.5.5 LAMEA Market size and forecast, by End-use
- 8.5.6 LAMEA Market size and forecast, by country
  - 8.5.6.1 Brazil
  - 8.5.6.1.1 Market size and forecast, by Product
  - 8.5.6.1.2 Market size and forecast, by Technique
  - 8.5.6.1.3 Market size and forecast, by Application
  - 8.5.6.1.4 Market size and forecast, by End-use
  - 8.5.6.2 Saudi Arabia
  - 8.5.6.2.1 Market size and forecast, by Product
  - 8.5.6.2.2 Market size and forecast, by Technique
  - 8.5.6.2.3 Market size and forecast, by Application
  - 8.5.6.2.4 Market size and forecast, by End-use
  - 8.5.6.3 UAE
  - 8.5.6.3.1 Market size and forecast, by Product
  - 8.5.6.3.2 Market size and forecast, by Technique
  - 8.5.6.3.3 Market size and forecast, by Application
  - 8.5.6.3.4 Market size and forecast, by End-use
  - 8.5.6.4 South Africa
  - 8.5.6.4.1 Market size and forecast, by Product
  - 8.5.6.4.2 Market size and forecast, by Technique
  - 8.5.6.4.3 Market size and forecast, by Application
  - 8.5.6.4.4 Market size and forecast, by End-use
  - 8.5.6.5 Rest of LAMEA
  - 8.5.6.5.1 Market size and forecast, by Product
  - 8.5.6.5.2 Market size and forecast, by Technique
  - 8.5.6.5.3 Market size and forecast, by Application
  - 8.5.6.5.4 Market size and forecast, by End-use

CHAPTER 9: COMPANY LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments

CHAPTER 10: COMPANY PROFILES

10.1 erba diagnostics mannheim gmbh
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
10.2 Bio-Rad Laboratories, Inc.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
10.3 Trinity Biotech Plc.
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
10.4 Thermo Fisher Scientific, Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
10.5 Antibodies Incorporated
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
10.6 euroimmun medizinische labordiagnostika ag
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
10.7 Immuno Concepts NA Ltd.
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
10.8 Inova Diagnostics, Inc.
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
10.9 ZEUS Scientific, Inc.
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments

抗核抗体検査市場：製品別、技術別、用途別、最終用途別：世界の機会分析および産業予測、2021-2031年

Antinuclear Antibody Test Market By Product, By Technique, By Application, By End-use : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章抗核抗体検査市場：製品別

第5章抗核抗体検査市場：技術別

第6章抗核抗体検査市場：応用分野別

第7章抗核抗体検査市場：エンドユース別

第8章抗糖尿素検査市場：地域別

第9章企業情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE

CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION

CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE

CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION

CHAPTER 9: COMPANY LANDSCAPE

CHAPTER 10: COMPANY PROFILES

抗核抗体検査市場：製品別、技術別、用途別、最終用途別：世界の機会分析および産業予測、2021-2031年

Antinuclear Antibody Test Market By Product, By Technique, By Application, By End-use : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 抗核抗体検査市場：製品別

第5章 抗核抗体検査市場：技術別

第6章 抗核抗体検査市場：応用分野別

第7章 抗核抗体検査市場： エンドユース別

第8章 抗糖尿素検査市場：地域別

第9章 企業情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE

CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION

CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE

CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION

CHAPTER 9: COMPANY LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章抗核抗体検査市場：製品別

第5章抗核抗体検査市場：技術別

第6章抗核抗体検査市場：応用分野別

第7章抗核抗体検査市場：エンドユース別

第8章抗糖尿素検査市場：地域別

第9章企業情勢

第10章企業プロファイル